Vaginal Uphold Hysteropexy and Laparoscopic Sacral Hysteropexy for the Treatment of Uterovaginal Pelvic Organ Prolapse (VAULT)
This study is currently recruiting participants.
Verified January 2013 by The Cleveland Clinic
Sponsor:
The Cleveland Clinic
Collaborators:
The Christ Hospital
Washington Hospital Center
Providence Healthcare in British Columbia
Stanford University
Women and Infants Hospital of Rhode Island
Greater Baltimore Medical Center
University of North Carolina
Information provided by (Responsible Party):
The Cleveland Clinic
ClinicalTrials.gov Identifier:
NCT01377142
First received: June 10, 2011
Last updated: January 11, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate surgical success or failure one year after surgery for pelvic organ prolapse.
| Condition |
|---|
|
Pelvic Organ Prolapse |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Vaginal Uphold Hysteropexy and Laparoscopic Sacral Hysteropexy for the Treatment of Uterovaginal Pelvic Organ Prolapse |
Resource links provided by NLM:
Further study details as provided by The Cleveland Clinic:
Primary Outcome Measures:
- The primary outcome measure will be surgical "success" or "failure" as a dichotomous outcome 1 year after surgery. Subjects will be considered a success if they meet the definitions of anatomic cure and deny vaginal bulging symptoms. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Anatomic sure is defined as cervix above mid-vagina, and no prolapse beyond the hymen and no surgical treatment for pelvic organ prolapse or pessary use.
Symptomatic cure is defined as the absence of vaginal bulge symptoms as indicated by a negative response question 3 of the pelvic floor distress inventory- 20.
Secondary Outcome Measures:
- Anatomic outcomes [ Time Frame: 12 months ] [ Designated as safety issue: No ]Evaluation of the anterior and posterior walls using point Aa, Ba, Ap and Bp, C, posterior fornix D and total vaginal length TVL; evaluate the size of the genital hiatus and perineal body; evaluation of cervical elongation and record any additional surgical procedures for anterior and posterior vaginal wall prolapse.
- Symptomatic improvement [ Time Frame: 3months and 12 months ] [ Designated as safety issue: No ]Relief of symptoms of pelvic floor disorders, including incontinence, voiding dysfunction, pelvic organ prolapse, fecal incontinence defecation disorders and sexual dysfunction using validated instruments collected postoperatively at 3 months, and 1 year.
- Shortterm morbidity [ Time Frame: 6 weeks, 3 months, 12 months ] [ Designated as safety issue: Yes ]We will compare the treatment groups with respect to perioperative morbidity and mortality. Perioperative morbidity will be recorded at completion of surgery and at hospital discharge. Postoperative morbidity will be recorded at any time after discharge- 6 weeks, 3 months and 1 year and all adverse events will be documented. Perioperative measures of morbidity will include operative time, estimated blood loss, and complications. Length of hospital stay will also be recorded. Complications will be categorized using the Dindo surgical complication grading scale.
- Pain and functional activity [ Time Frame: 6 weeks and 6 months ] [ Designated as safety issue: No ]Postoperative pain- subjects will complete the modified surgical pain scale and a diary of pain medication use preoperatively, then daily for two weeks after surgery, then again at 6 weeks postoperatively. Postoperative functional activity level- subjects will complete the activity assessment scale which measures postoperative functional activity preoperatively, 2 weeks, 6 weeks and 6 months after surgery.
| Estimated Enrollment: | 144 |
| Study Start Date: | June 2011 |
| Estimated Study Completion Date: | March 2014 |
| Estimated Primary Completion Date: | March 2014 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
| Laparoscopic sacral hysteropexy treatment |
| Vaginal uphold hysteropexy treatment |
Eligibility| Ages Eligible for Study: | 40 Years to 75 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Adult women with symptomatic uterovaginal prolapse planning to undergo laparsocopic sacral hysteropexy or vaginal uphold hysteropexy
Criteria
Inclusion Criteria:
- Desires surgical treatment for uterovaginal prolapse.
- Symptomatic stage II-IV POP including:
- cystocele (AA or BA > or = 0) by POP-Q and
- apical descent below the mid-vagina (point C > -(TVL / 2)) by the POP-Q and
- a positive response to questions 3 of the PFDI 20: Do you usually have a bulge or something falling out that you can see or feel in the vaginal area? (Appendix A)
- Eligible for and undergoing one of the following procedures: laparoscopic sacral hysteropexy (LSHP) or Vaginal Uphold hysteropexy (VUHP)
- Female age 40 to 75.
- Completed childbearing confirmed by subject or practicing reliable form of birth control defined as permanent sterilization, hormonal contraception, abstinence, IUD.
- Normal size uterus (length less than 10 cm) on bimanual exam or ultrasound within the past 6 months.
Exclusion Criteria:
- Prior hysterectomy.
- Patient with synthetic material placed to augment previous pelvic organ prolapse repair. (previous prolapse repair without synthetic mesh is acceptable).
- Current vaginal or pelvic foreign body complications (including but not limited to erosion, fistula, abscess). This includes foreign bodies of any type (e.g. synthetic and biologic including allograft, xenograft).
- Desires hysterectomy at the time of prolapse repair.
- Cervical elongation with anticipated need for cervical shortening at the time of prolapse repair as determined by surgeon.
- History of cervical dysplasia (diagnosed within the past 5 years) or increased risk of cervical dysplasia (HIV, immunocompromise, DES exposure), chronic pelvic pain, uterine abnormalities (symptomatic uterine fibroids, polyps, endometrial hyperplasia, cancer) or any uterine disease that would preclude prolapse repair with uterine preservation in the opinion of the surgeon.
- Any postmenopausal bleeding in the past 12 months (regardless of endometrial biopsy or ultrasound results) or any postmenopausal bleeding more than 12 months prior without adequate evaluation in the opinion of the investigator.
- Premenopausal women with menstrual issues including irregular bleeding, menorrhagia, dysmenorrhea,
- Pregnancy (confirmed before surgery with a pregnancy test).
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01377142
Contacts
| Contact: Matthew D. Barber, MD, MHS | 216-445-8090 | barberm2@ccf.org |
| Contact: Geetha Krishnan, RN | 216-445-8090 | krishng@ccf.org |
Locations
| United States, California | |
| Stanford University | Recruiting |
| Stanford, California, United States, 94305 | |
| Contact: Tine Bjornlund 650-724-7826 tbjorn@stanford.edu | |
| Principal Investigator: Eric Sokol, MD | |
| United States, District of Columbia | |
| Washington Hospital | Recruiting |
| Washington, District of Columbia, United States, 20010 | |
| Contact: Joanna Peterson, RN 202-877-0526 joanna.l.peterson@medstar.net | |
| Principal Investigator: Robert E. Gutman, MD | |
| United States, Maryland | |
| Greater Baltimore Medical Center | Recruiting |
| Baltimore, Maryland, United States, 21204 | |
| Contact: Sue Aumiller 443-849-8049 saumille@gbmc.org | |
| Principal Investigator: Joan Blomquist, MD | |
| United States, North Carolina | |
| UNC | Recruiting |
| Chapel Hill, North Carolina, United States, 27599 | |
| Contact: Vanessa Hightower-Corbett 919-843-1862 vanessa_hightower-corbett@med.unc.edu | |
| Principal Investigator: Catherine Matthews, MD | |
| United States, Ohio | |
| The Christ Hospital | Recruiting |
| Cincinnati, Ohio, United States, 45069 | |
| Contact: Marsha Zartman 513-463-2509 marsha.zartman@thechristhospital.com | |
| Contact: Sharon Lamping 513-463-2500 sharon.lamping@thechristhospital.com | |
| Principal Investigator: Mickey Karram, MD | |
| Cleveland Clinic | Recruiting |
| Cleveland, Ohio, United States, 44195 | |
| Contact: Geetha Krishnan, RN, MSN 216-445-8090 krishng@ccf.org | |
| Principal Investigator: Matthew D. Barber, MD, MHS | |
| United States, Rhode Island | |
| Women & Infant's Hospital | Recruiting |
| Providence, Rhode Island, United States, 02903 | |
| Contact: Ann Mears, RN 401-274-1122 ext 2811 amears@wihri.org | |
| Contact: Samantha Douglas 401-276-7869 sdouglas@wihri.org | |
| Principal Investigator: Charles Rardin, MD | |
| Canada, British Columbia | |
| Providence Healthcare | Recruiting |
| Vancouver, British Columbia, Canada, V6Z1Y6 | |
| Contact: Nikki Koenig 604-806-9829 nkoenig@providencehealth.bc.ca | |
| Principal Investigator: Geoffrey Cundiff, MD | |
Sponsors and Collaborators
The Cleveland Clinic
The Christ Hospital
Washington Hospital Center
Providence Healthcare in British Columbia
Stanford University
Women and Infants Hospital of Rhode Island
Greater Baltimore Medical Center
University of North Carolina
Investigators
| Principal Investigator: | Robert E Gutman, MD | Washington Hospital Center |
More Information
No publications provided
| Responsible Party: | The Cleveland Clinic |
| ClinicalTrials.gov Identifier: | NCT01377142 History of Changes |
| Other Study ID Numbers: | 11-409 |
| Study First Received: | June 10, 2011 |
| Last Updated: | January 11, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by The Cleveland Clinic:
|
Uterovaginal prolapse hysteropexy mesh |
Additional relevant MeSH terms:
|
Prolapse Pelvic Organ Prolapse Pathological Conditions, Anatomical |
ClinicalTrials.gov processed this record on May 22, 2013